Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Conflict of Interest!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1)
•••
Comment by CalgaryATEon Apr 18, 2021 8:57pm
175 Views
Post# 33019920

RE:Conflict of Interest!

RE:Conflict of Interest!Holdings' 15% royalties is worth 15% of the amalgamated company no matter what the current share price. Holdings will get about 10 million shares (10/66=15%), while ATE shareholders will retain 56 million shares (56/66=85%). Why would the current share price affect how the royalties (profit for simplicity's sake) be divided up?
JPkatz wrote: So who's side is Dan going to be on in this amalgamation? The side he and Wallace own a combined 50% or we the dumb retail holders? I think anyone with half a brain can answer that and we as shareholders can be expected to get to get raked through the coals once again no doubt... No wonder the downward trend and lack of buying interest as smart money is waiting for this charade to play out!!


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities